Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSH | P09668 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 5/20 | 0.46 |
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7358261 | 0.89 | CASP3 (0.52) | CTSKCTSBCTSSCTSHCTSC | |
| SCHEMBL7358268 | 0.89 | CASP3 (0.52) | CTSKCTSBCTSSCTSHCTSC | |
| SCHEMBL7358274 | 0.89 | CASP3 (0.52) | CTSKCTSBCTSSCTSHCTSC | |
| SCHEMBL8127874 | 0.87 | CTSB (0.62) | CTSKCTSBCTSSCTSHCTSC | |
| SCHEMBL19015816 | 0.83 | CASP3 (0.51) | CTSKCTSBCTSSCTSHCTSC | |
| SCHEMBL7214816 | 0.83 | CASP3 (0.51) | CTSKCTSBCTSSCTSHCTSC | |
| SCHEMBL15459291 | 0.81 | CTSK (0.45) | CTSKCTSC | |
| SCHEMBL19015814 | 0.81 | CASP3 (0.48) | CTSKCTSBCTSSCTSHCTSC | |
| SCHEMBL7356705 | 0.80 | CTSK (0.54) | CTSKCTSBCTSSCTSHCTSC | |
| SCHEMBL7356711 | 0.80 | CTSK (0.54) | CTSKCTSBCTSSCTSHCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2019-01-01 | — | — | US | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | CTSK 83/4885CTSB 27/4885CTSS 47/4885 |
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | CTSK 83/4885CTSB 27/4885CTSS 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.